vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and TFS Financial CORP (TFSL). Click either name above to swap in a different company.

TFS Financial CORP is the larger business by last-quarter revenue ($83.7M vs $77.6M, roughly 1.1× Bioceres Crop Solutions Corp.). TFS Financial CORP runs the higher net margin — 26.6% vs -9.6%, a 36.2% gap on every dollar of revenue. On growth, TFS Financial CORP posted the faster year-over-year revenue change (11.9% vs -16.8%). Over the past eight quarters, TFS Financial CORP's revenue compounded faster (4.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

TFS Financial Corporation is a US-based financial holding company primarily operating through its retail banking subsidiary. It offers residential mortgage loans, savings accounts, and other consumer financial products, with its core customer base concentrated in Ohio and Florida, mainly serving individual and family clients.

BIOX vs TFSL — Head-to-Head

Bigger by revenue
TFSL
TFSL
1.1× larger
TFSL
$83.7M
$77.6M
BIOX
Growing faster (revenue YoY)
TFSL
TFSL
+28.7% gap
TFSL
11.9%
-16.8%
BIOX
Higher net margin
TFSL
TFSL
36.2% more per $
TFSL
26.6%
-9.6%
BIOX
Faster 2-yr revenue CAGR
TFSL
TFSL
Annualised
TFSL
4.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BIOX
BIOX
TFSL
TFSL
Revenue
$77.6M
$83.7M
Net Profit
$-7.4M
$22.3M
Gross Margin
46.8%
Operating Margin
9.3%
34.0%
Net Margin
-9.6%
26.6%
Revenue YoY
-16.8%
11.9%
Net Profit YoY
-20.2%
-0.7%
EPS (diluted)
$-0.12
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
TFSL
TFSL
Q4 25
$83.7M
Q3 25
$77.6M
$85.5M
Q2 25
$82.0M
Q1 25
$60.6M
$79.1M
Q4 24
$98.8M
$74.8M
Q3 24
$93.3M
$75.1M
Q2 24
$75.5M
Q1 24
$84.0M
$77.1M
Net Profit
BIOX
BIOX
TFSL
TFSL
Q4 25
$22.3M
Q3 25
$-7.4M
$26.0M
Q2 25
$21.5M
Q1 25
$-1.6M
$21.0M
Q4 24
$605.2K
$22.4M
Q3 24
$-6.2M
$18.2M
Q2 24
$20.0M
Q1 24
$9.8M
$20.7M
Gross Margin
BIOX
BIOX
TFSL
TFSL
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
TFSL
TFSL
Q4 25
34.0%
Q3 25
9.3%
37.9%
Q2 25
33.3%
Q1 25
1.5%
33.5%
Q4 24
14.5%
37.9%
Q3 24
2.5%
30.7%
Q2 24
33.4%
Q1 24
15.7%
33.6%
Net Margin
BIOX
BIOX
TFSL
TFSL
Q4 25
26.6%
Q3 25
-9.6%
30.4%
Q2 25
26.2%
Q1 25
-2.6%
26.6%
Q4 24
0.6%
30.0%
Q3 24
-6.6%
24.2%
Q2 24
26.4%
Q1 24
11.6%
26.9%
EPS (diluted)
BIOX
BIOX
TFSL
TFSL
Q4 25
$0.08
Q3 25
$-0.12
$0.09
Q2 25
$0.08
Q1 25
$-0.02
$0.07
Q4 24
$0.00
$0.08
Q3 24
$-0.10
$0.07
Q2 24
$0.07
Q1 24
$0.14
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
TFSL
TFSL
Cash + ST InvestmentsLiquidity on hand
$15.5M
$456.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$1.9B
Total Assets
$734.9M
$17.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
TFSL
TFSL
Q4 25
$456.7M
Q3 25
$15.5M
$429.4M
Q2 25
$452.6M
Q1 25
$38.5M
$463.6M
Q4 24
$29.2M
$465.9M
Q3 24
$32.3M
$463.7M
Q2 24
$560.4M
Q1 24
$16.4M
$594.3M
Stockholders' Equity
BIOX
BIOX
TFSL
TFSL
Q4 25
$1.9B
Q3 25
$288.3M
$1.9B
Q2 25
$1.9B
Q1 25
$345.0M
$1.9B
Q4 24
$346.3M
$1.9B
Q3 24
$346.0M
$1.9B
Q2 24
$1.9B
Q1 24
$348.5M
$1.9B
Total Assets
BIOX
BIOX
TFSL
TFSL
Q4 25
$17.5B
Q3 25
$734.9M
$17.5B
Q2 25
$17.4B
Q1 25
$798.2M
$17.1B
Q4 24
$835.2M
$17.1B
Q3 24
$827.3M
$17.1B
Q2 24
$17.0B
Q1 24
$836.1M
$17.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
TFSL
TFSL
Operating Cash FlowLast quarter
$14.4M
$58.7M
Free Cash FlowOCF − Capex
$57.1M
FCF MarginFCF / Revenue
68.2%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
2.64×
TTM Free Cash FlowTrailing 4 quarters
$167.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
TFSL
TFSL
Q4 25
$58.7M
Q3 25
$14.4M
$82.4M
Q2 25
$26.8M
Q1 25
$23.3M
$21.2M
Q4 24
$-5.4M
$45.5M
Q3 24
$5.2M
$88.6M
Q2 24
$96.7M
Q1 24
$-17.4M
$14.2M
Free Cash Flow
BIOX
BIOX
TFSL
TFSL
Q4 25
$57.1M
Q3 25
$71.0M
Q2 25
$25.0M
Q1 25
$14.3M
Q4 24
$44.9M
Q3 24
$85.5M
Q2 24
$95.9M
Q1 24
$13.4M
FCF Margin
BIOX
BIOX
TFSL
TFSL
Q4 25
68.2%
Q3 25
83.0%
Q2 25
30.5%
Q1 25
18.0%
Q4 24
60.0%
Q3 24
113.8%
Q2 24
127.0%
Q1 24
17.4%
Capex Intensity
BIOX
BIOX
TFSL
TFSL
Q4 25
2.0%
Q3 25
13.4%
Q2 25
2.1%
Q1 25
8.8%
Q4 24
0.9%
Q3 24
4.1%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
BIOX
BIOX
TFSL
TFSL
Q4 25
2.64×
Q3 25
3.17×
Q2 25
1.24×
Q1 25
1.01×
Q4 24
-8.85×
2.03×
Q3 24
4.86×
Q2 24
4.85×
Q1 24
-1.78×
0.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons